Search results - Portal of Medical Data Models (MDM-Portal)

Palliative and Hospice Care Advanced Diagnostic Procedures

- 5/11/16 - 1 form, 9 itemgroups, 59 items, 2 languages

Itemgroups: Microbiological tests, Therapeutic consequences from laboratory result, Ultrasound, X-ray, CT / MRI, radio imaging, Issues during diagnostic imaging, Therapeutic consequences from diagnostic imaging, Form Information

https://www.hope-clara.de/ The HOPE Hospice and Palliative Care Recording standard documentation is used for documentation of palliative care and as an instrument for quality assurance in pallatiave wards, hospices and oncological wards as well as in ambulatory services and palliative teams.

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Cumulative documentation - Procedures (Kumulative Dokumentation - Prozeduren)

- 3/23/20 - 1 form, 2 itemgroups, 6 items, 1 language

Itemgroups: Administrative Data, Procedures

DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the cumulative documentation - procedures. Prior procedures should be filled in at baseline. Procedures that are performed during the study period should be added in the course of the study.

Emergency MS Outpatient Department Neurology University Hospital Essen - Emergency

- 3/27/17 - 1 form, 1 itemgroup, 4 items, 1 language

Itemgroup: Emergency

Documentation form "Notfall" converted to ODM format. Routine documentation of University Hospital of Essen. Publication granted by: Priv.-Doz. Dr. med. Benedikt, University Hospital of Essen, Essen, Germany.

Angiography request, University Hospital Cologne

- 4/16/17 - 1 form, 2 itemgroups, 25 items, 1 language

Itemgroups: RIS Request, Angiography Request

Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: Angiograph_Anford

DESCRIBE (DZNE – Clinical Register Study of neurodegenerative Disorders) CRF Diagnostic Criteria - CRF Diagnostic Criteria

- 9/20/21 - 1 form, 20 itemgroups, 378 items, 1 language

Itemgroups: Date of visit, Mild cognitive impairment (MCI), Dementia in Alzheimer's Disease (AD), Posterior cortical atrophy (PCA), Vascular dementia, Frontotemporal dementia, behavioral variant, Primary progressive aphasia (PPA), Progressive nonfluent aphasia (PNFA), Logopenic progressive aphasia (LPA), Semantic dementia (SemD), Idiopathic Parkinson's disease (IPS), Morbus parkinson along with MCI (PD-MCI), Dementia in Parkinsons disease, Dementia with Lewy bodies (DLB), Progressive supranuclear palsy, Corticobasal degeneration (CBD), Multiple system atrophy (MSA), Essential tremor (ET), Amyotrophic lateral sclerosis (ALS), Depression

Background and Purpose: The purpose of the DESCRIBE study is to document the natural course of diseases in context of medical care of neurodegenerative disorders as well as cerebrovascular diseases and to perform phenotyping of the test persons. Disease-spanning analyses of the measured clincial data, the results of the imaging processes, results of the analysis of the biometerials including genetic analysis are planed. Principal Investigator: Prof. Klockgether, Dr. Spottke DZNE, Bonn. Source: DESCRIBE-Studie http://www.dzne.de/forschung/forschungsbereiche/klinische-forschung/studien/describe-bn006.html Participating Study Sites: Berlin, Bonn, Göttingen, Dresden, Köln, Magdeburg, München, Rostock/Greifswald, Tübingen

Eligibility Recurrent Prostate Cancer NCT00775866

- 6/10/17 - 1 form, 2 itemgroups, 18 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00775866

Emotional processing in healthy male volunteers treated with GSK424887 NCT01424384 - Non- Serious and Serious Adverse Event

- 8/27/18 - 1 form, 7 itemgroups, 51 items, 1 language

Itemgroups: Non-serious Adverse Event, Serious Adverse Event, Pharmaceutical Preparations | Concomitant Therapy, Disease | risk factors, diagnostic procedure; Result, Experimental drug, Comment

Study ID: 105012 Clinical Study ID: NSS105012 Study Title: Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01424384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK424887 Trade Name: Citalopram Study Indication: Depressive Disorder and Anxiety Disorders

FEES Neurology, University Hospital Cologne

- 4/20/17 - 1 form, 4 itemgroups, 31 items, 1 language

Itemgroups: FEES, FEES at rest, Evaluation of swallowing without food, Evaluation of swallowing with food

Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: FEES_Neurologie

BE MS Neuro USD LSTM Sub MS University Hospital Muenster (UKM) Subform

- 11/27/16 - 1 form, 1 itemgroup, 21 items, 1 language

Itemgroup: General information section

Hospital Routine Documentation Subform at the University Hospital Muenster. Original Form name: BE MS Neuro USD LSTM Sub.

Q181 16 Diag Brust University Hospital Muenster (UKM) Subform

- 11/13/16 - 1 form, 1 itemgroup, 11 items, 1 language

Itemgroup: Breast Status

Hospital Routine Documentation Subform at the University Hospital Muenster. Original Form name: Q181 16 Diag Brust

dental examination SHIP-Trend-1 DEX: Chewing Gum Test Scan

- 1/24/21 - 1 form, 1 itemgroup, 5 items, 2 languages

Itemgroup: DEX: Chewing Gum Test Scan

DEX: Chewing Gum Test Scan form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name TREND.TREND1.DEX.DEXCGT.DEXCGTSCAN. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

GSK Study: Evaluation of safety and efficacy of VarilrixTM and of Combined Measles-Mumps-Rubella-Varicella Vaccine NCT00226499 - Rash, Parotid swelling, Febrile convulsion

- 8/26/17 - 1 form, 6 itemgroups, 42 items, 1 language

Itemgroups: Rash / Exanthema, Rash /exanthem, Parotid / Salivary gland swelling events, Parotid / Salivary gland swelling events, Febrile convulsions - Suspected signs of meningism events, Febrile convulsions - Suspected signs of meningism events

GSK Study: Evaluation of safety and efficacy of VarilrixTM and of Combined Measles-Mumps-Rubella-Varicella Vaccine NCT00226499 - Rash/Exanthem, Parotid swelling and febrile convulsion Study ID: 100388 Clinical Study ID: 100388 Study Title: Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00226499 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Varicella Vaccine Trade Name: BIO OKAH; Varilrix Study Indication: Varicella

Keywords

Table of contents

Selected data models